Summary
DexCom Inc.'s 2020 10-K filing highlights a significant year of growth and product development, with a primary focus on their continuous glucose monitoring (CGM) systems, particularly the DexCom G6. The company has seen substantial revenue growth, driven by increased sales volume of disposable sensors, indicating expanding customer adoption of their technology. DexCom continues to invest heavily in research and development to enhance product performance and convenience, aiming to integrate their CGM technology with insulin delivery systems and expand their market reach to new patient populations and healthcare settings. Despite facing pricing pressures and ongoing competitive challenges, DexCom's strategic focus on technological advancement and market expansion positions it for continued growth in the diabetes management sector.
Financial Highlights
51 data pointsBeta
Financial Statements
Beta
| Revenue | $1.48B |
| Cost of Revenue | $544.50M |
| Gross Profit | $931.50M |
| R&D Expenses | $273.50M |
| SG&A Expenses | $515.70M |
| Operating Expenses | $789.20M |
| Operating Income | $142.30M |
| Interest Expense | $60.30M |
| Net Income | $101.10M |
| EPS (Basic) | $0.28 |
| EPS (Diluted) | $0.28 |
| Shares Outstanding (Basic) | 364.40M |
| Shares Outstanding (Diluted) | 369.20M |
Key Highlights
- 1DexCom reported substantial revenue growth of 43% in 2019, reaching $1.476 billion, primarily driven by increased sales volume of disposable sensors.
- 2The company launched its latest generation system, the DexCom G6 integrated Continuous Glucose Monitoring System (iCGM), in 2018, which received FDA authorization and CE Mark approval, enabling integration with automated insulin dosing systems.
- 3DexCom continues to invest significantly in research and development (R&D), with R&D expenses increasing by 37% in 2019 to $273.5 million, reflecting a commitment to innovation and new product development.
- 4The company has a strategic focus on expanding its market reach beyond Type 1 and insulin-dependent Type 2 diabetes patients to include non-insulin users, pre-diabetes, obese individuals, pregnant women, and hospital settings.
- 5DexCom has established key partnerships with major insulin pump manufacturers like Eli Lilly, Insulet, Novo Nordisk, and Tandem Diabetes, aiming to integrate their CGM technology for enhanced diabetes management solutions.
- 6The company's financial position remains strong, with $1.53 billion in cash, cash equivalents, and marketable securities as of December 31, 2019, providing ample resources for ongoing operations and future investments.
Frequently Asked Questions
DexCom's primary products are continuous glucose monitoring (CGM) systems designed for people with diabetes and healthcare providers. Their flagship product is the DexCom G6 integrated Continuous Glucose Monitoring System. The company targets individuals with Type 1 and Type 2 diabetes, particularly those using insulin pumps or multiple daily injections, and plans to expand its market to other patient groups like those with Type 2 diabetes on oral medications, pre-diabetes, and hospital patients.
DexCom has experienced significant revenue growth. In 2019, total revenue increased by 43% to $1.476 billion, driven primarily by higher sales volumes of disposable sensors. The company's gross profit also saw a substantial increase, though gross margin slightly decreased due to channel strategy evolution, product mix, and investments in infrastructure.
Key growth drivers for DexCom include the continued adoption of its advanced CGM technology, particularly the G6 system, expansion into new patient populations and international markets, strategic partnerships with insulin delivery companies to create integrated diabetes management solutions, and ongoing investment in research and development to drive product innovation and performance improvements.
DexCom faces several risks, including intense competition from established medical device companies, potential manufacturing and supply chain disruptions, reliance on third-party reimbursement from payors which can be restrictive, product liability claims, intellectual property disputes, and the need for continuous innovation and timely regulatory approvals for new products. They also highlight risks related to their significant debt obligations from convertible notes.